natgillin/translations-raw huggingface dataset:
The method according to Claim 26, wherein the antigen is loaded onto class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell by contacting a sufficient amount of the antigen with an antigen-presenting cell. 
Metoda sukladno Tvrdnji 20, pri čemu se antigen nalazi na molekulama MHC klase I koje su izražene na površini prikladne stanice koja predstavlja antigen kontaktiranjem dovoljne količine antigena sa stanicom koja predstavlja antigen.
The method of claim 40 wherein the crop and/or application are moving. 
Postupak prema zahtjevu 40, naznačen time što se usjev i/ili nanošenje kreću.
a flow rate sensor configured to supply an electric signal of which at least one of the characteristics varies according to the flow rate circulating to the secondary water outlet; 
○ senzor protoka (4D-5) koji proizvodi električni signal, čija se najmanje jedna karakteristika mijenja u skladu s brzinom protoka vode koja struji prema sekundarnom izlazu vode (4D-3 ili 4F-3);
and Rb independently represent an Ra group or a -Y-carbocyclic or -Z-heterocyclyl group wherein said carbocyclic and heterocyclyl groups may be optionally substituted by 1, 2 or 3 Ra groups; 
i Rb neovisno predstavlja Ra grupu ili -Y-karbocikličnu ili -Z-heterociklil grupu, pri čemu spomenute karbociklične i heterociklil grupe mogu biti opcionalno supstituirane s 1, 2 ili 3 Ra grupe;
at least one non-intrusive mobile suction means (3) for moving along the bottom of said at least one containing means (12) and suctioning water containing settled particles, wherein the mobile suction means (3) is configured to perform a surface cleaning of the receiving means (2); 
najmanje jedno neometano mobilno sredstvo za usisavanje (3) za pomicanje duž dna navedenog najmanje jednog sredstva za sadržavanje i usisavanje vode koja sadrži nataložene čestice;
The self-drilling screw according to claim 1, wherein the topcoat (4) comprises a layer which intrinsically has differences in layer thickness of up to +/−60%. 
Vijak za bušenje sukladno jednom od prethodnih patentnih zahtjeva, naznačen time što završni sloj (4) sadrži sloj koji kao takav ima razlike u debljini sloja maksimalno od +/- 60%.
Compounds of Formula IIB 
Spoj formule IIB:
The compounds above may suitably be provided in the form of a pharmaceutically acceptable salt, preferably the hydrochloride salt. 
Spoj za upotrebu prema zahtjevu 8, naznačen time što je spoj s formulom I osiguran u obliku hidrokloridne soli.
Examples of suitable cholesterol absorption inhibitor for use in combination with the compound of the invention include SCH48461 (Schering-Plough), as well as those disclosed in Atherosclerosis 115, 45-63 (1995) and J. Med. 
Primjeri pogodnih inhibitora apsorpcije kolesterola za primjenu u kombinaciji sa spojem prema izumu obuhvaćaju SCH48461 (Schering-Plough), kao i one navedene u Atherosclerosis 115, 45-63 (1995) 1 J. Med.
The process according to any one of claims 1 to 5, wherein the cortexolone-17a-propionate is prepared by reacting a compound of Formula IIa: wherein R is CH3CH2, with a compound of Formula III R'OH (III) wherein R' is a linear aliphatic chain containing 1-10 carbon atoms to give cortexolone-17a-propionate, in the presence of a lipase from Candida. 
(ID), u prisutnosti lipaze iz kvasca Candida, gdje R je CH3-CH>, a R' je nerazgranati alifatski lanac, koji sadrži 1-10 atoma ugljika, kako bi se dobilo korteksolon-17a-propionat, te kristaliziranju navedenog korteksolon-17a- propionata iz smjese diklormetan/n-heksan, ili smjese aceton/n-heksan ili smjese etanol/voda, kako bi se dobilo korteksolon-17a-propionat u kristalnom obliku III.
An isolated human antibody or antigen-binding fragment thereof that specifically binds to, or blocks the biological activity of wild-type mature human GDF8 comprising SEQ ID NO: 340, but does not bind to, or block the biological activity of a chimeric GDFB/TGFB1 construct having amino acids 48-72 of mature human GDF8 replaced with the corresponding amino acid sequence of TGFB1, wherein the chimeric GDF8/TGF1 construct comprises the amino acid sequence of SEQ ID NO: 352, and wherein the antibody or antigen-binding fragment comprises: (a) HCDR1/HCDR2/HCDR3 amino acid sequences consisting of SEQ ID NOs: 362/364/366, respectively and (b) LCDR1/LCDR2/LCDR3 amino acid sequences consisting of SEQ ID NOs: 370/372/374, respectively. 
Izolirano humano protutijelo ili njegov fragment koji se veže na antigen, naznačen time, da se specifično veže na ili blokira biološku aktivnost divljeg tipa zrelog humanog GDF8 koji sadržava SEQ ID NO: 340, ali se ne veže na ili blokira biološku aktivnost himernog GDFB/TGF01 konstrukta koji sadržava aminokiseline 4872 zrelog humanog GDF8 zamijenjene odgovarajućom aminokiselinskom sekvencom TGFpi, pri čemu himerni GDF8/TGF01 konstrukt sadržava aminokiselinsku sekvencu SEQ ID NO: 352, i pri čemu protutijelo ili fragment koji veže antigen sadržava:
The method of claim 6, wherein any one or more of the following applies, said clear filtrate solution is transferred to another clean vessel for recrystallizing the product; and 
Postupak prema zahtjevu 17, naznačen time da se navedena bistra otopina filtrata prebacuje u drugu čistu posudu radi navedenog taloženja.
Use according to claim 8 or 9, wherein said disorder involves an elevated pH and/or a disturbed microbiota in the urogenital tract. 
Uporaba sukladno patentnom zahtjevu 7 ili 8, pri tome spomenuti poremećaj uključuje povišeni pH i/ili poremećaj mikroflore u urogenitalnom traktu.
The polypeptide according to any of the preceding claims, wherein the polypeptide binds to an IL-17F mutant with reduced affinity as compared to binding to the wildtype human IL-17F sequence, wherein the IL-17F mutant comprises one or more mutations of R47A, I86A, and N89A. 
Polipeptid prema bilo kojem od zahtjeva 1-5, naznačen time da se polipeptid specifično veže na ljudski IL-17 F, pri čemu se polipeptid veže na R47A i/ili R73A i/ili I86A i/ili N89A IL-17F mutant sa značajno smanjenim afinitetom u usporedbi s vezanjem na divlji tip IL-17F sekvence.
Rb is selected from the group consisting of hydrogen, C1-4 alkyl and aryl C1-4 alkyl; 
Rb se bira iz skupine koju čine vodik, C1-4 alkil 1 aril C1-4 alkil;
further comprising executing program instructions on the one or more processors to automatically record the fraction of fetal of DNA as estimated in (c) in a patient medical record, stored on a computer readable medium, for the pregnant individual; further comprising, based on the estimate of the fraction of fetal DNA, prescribing, initiating, and/or altering treatment of a human subject from whom the maternal test sample was taken; 
Postupak prema patentnom zahtjevu 1, naznačen time što nadalje sadrži izvršavanje programskih uputa u okviru jednog ili više procesora radi automatskog snimanja frakcije fetusne DNK koja je procijenjena u (c) u medicinski karton trudne osobe, kao i čuvanje na mediju koji može biti očitan od pomoću računala.
A method according to claim 11, wherein said third monomers are streptavidin and/or said second monomers are Streptag I (SEQ ID NO. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time, da su navedeni treći monomeri streptavidin i/ili navedeni drugi monomeri su Streptag I (SEQ ID NO.
recycling at least a portion of said fuel gas to a second hydrogen generator, which is an autothermal reformer (ATR), to form a supplemental syngas stream; and (f) combining said supplemental syngas stream with the hydrogen lean stream. 
(e) recikliranja u najmanju ruku dijela navedenog plinovitog goriva u drugi generator vodika, koji je autotermalni reformer (ATR), kako bi se dobilo dodatnu struju sinteznog plina; i (D kombiniranja navedene dodatne struje sinteznog plina sa strujom siromašnom vodikom.
A macromolecule for use as claimed in Claim 6, wherein the macromolecule is administered in an amount of from 30 mg to 200 mg per dose, or 40 mg to 160 mg per dose. 
Makromolekula za uporabu u skladu s patentnim zahtjevom 6, pri čemu je makromolekula primijenjena u količini od 30 mg do 200 mg po dozi, ili 40 mg do 160 mg po dozi.
at least about 15 µg compound of formula (3)/kg/minute. 
najmanje 15 µg spoja sa formulama (1) ili (2)/kg/minuti.
a negative signal in a SNP assay using a SNP-probe comprising the nucleotide sequence described by SEQ ID NO: 12 and a positive signal using a SNP-probe comprising the nucleotide sequence described by SEQ ID NO: 11, 
pozitivni signal u SNP testu korištenjem SNP-sonde koja sadrži nukleotidnu sekvencu opisanu sa SEQ ID NO: 11 i negativni signal korištenjem SNP-sonde koja sadrži nukleotidnu sekvencu opisanu sa SEQ ID NO: 12, i
reacting the compound of formula (IV), or a salt thereof, with N-hydroxysuccinimide in the presence of the coupling agent 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) to form the compound of formula (V) or a salt thereof. 
reakciju spoja formule (IV), ili njegove soli, s N-hidroksisukcinimidom u prisutnosti baze, da se dobije sol spoja s formulom (V); i
A cloning or expression vector comprising one or more polynucleotide sequences of claim 21 . 
Vektor kloniranja ili vektor ekspresije naznačen time da sadrži jednu ili više polinukleotidnih sekvenci prema zahtjevu 27.
The method according to claim 1, wherein when the semimanufactured component of the upper is folded back and closed, the membrane substantially duplicates the shape of the upper. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da je prema njemu gornjište (12) preklopljeno unatrag i zatvoreno.
"acylamido", as used herein, pertains to a -NR1C(=O)R2 group, wherein R1 hydrogen, a C1-7 alkyl group, a C3-20 heterocyclyl group, or a C5-20 aryl group, R2 is a C1-7 alkyl group, a C3-20 heterocyclyl group, or a C5-20 aryl group, or R1 and R2 may together with the atoms to which they are attached form a succinimidyl, maleimidyl, and phthalimidyl group; 
"acilamido", kako se ovdje koristi, odnosi se na -NR'C(=O)R* skupinu, pri čemu R' je vodik, C,.; alkilna skupina, C3.20 heterociklilna skupina, ili C5.29 arilna skupina, R? je Cig alkilna skupina, C3.24 heterociklilna skupina, ili C5.29 arilna skupina, ili R' i R* mogu zajedno sa atomima na koje su vezani tvoriti sukcinimidil, maleimidil, i ftalimidil skupinu;
A use according to claim 6 or 7, wherein the renin inhibitor is a δ-amino-Y-hydroxy-w-aryl alkanoic acid amide derivative, or a pharmaceutically acceptable salt thereof. 
Uporaba u skladu sa zahtjevom 26, naznačena time, da inhibitor renina je derivat amida δ-amino-Y-hidroksi-w-aril-alkanoične kiseline, ili je njegova farmaceutski prihvatljiva sol.
According to the invention, the beam-like block of wood is watered prior to the cutting, whereby the watering preferably is carried out at an increased temperature, preferably at a temperature of > 60 °C, more preferred at a temperature of > 70 °C, in particular at a temperature between 75 and 85 °C. 
U skladu s ovim izumom, blok od drva koji ima oblik grede se potapa u vodu prije rezanja, pri čemu je poželjno da se namakanje izvodi na povišenoj temperaturi, poželjno na temperaturi od > 60"C, još poželjnije na temperaturi od > 70""C, naročito na temperaturi između 75 i $5%C.
A pharmaceutical suspension as in claim 1 wherein the viscosity of the suspension is greater than 15 cps but no greater than 1000 cps wherein the viscosity of the suspension is measured at a high shear rate of 46 sec-1 at room temperature. 
Suspenzija za uporabu prema bilo kojem od zahtjeva 14 do 15, naznačena time, da je viskozitet suspenzije veći od 15 cP (mPas), ali nije veći od 1000 cP (mPas), dok se viskozitet suspenzije mjeri uporabom viskozimetra Brookfiels LV s
A method according to claim 1 wherein said inflammatory edema is thrombin-induced edema. 
Inhibitor za uporabu sukladno patentnom zahtjevu 1 naznačen time što navedeni upalni edem je edem prouzročen trombinom.
The process according to claim 3, wherein the fixing of the half shells occurs by spot or continuous welding with an automatic welding system. 
Postupak prema zahtjevu 2, gdje se fiksiranje polu-okvira (1, 1') obavlja pomoću točkastog ili kontinuiranog zavarivanja s automatskim sustavom za zavarivanje (21; 23).
Compound 67 was obtained as an orange oil from 2-fluoronitrobenzene and N,N-dimethyl-ethylenediamine by method H. 
Spoj 67 se dobiva kao narančasto ulje iz 2-fluornitrobenzena i N,N-dimetil-etilendiamina pomoću postupka H.
where X and Y are leaving groups and R1, R2, R3, R4, R5 and R8 are as defined in claim 1. 
pri čemu su X i Y izlazne skupine i R1, R2, R3, R4, R5 i R8 su isti kao što su definirani u zahtjevu 1.
The aqueous pharmaceutical-suspension according to claim 7, optionally further comprising, by weight/volume (g/100 mL), about 2.5% to about 5.0% of propylene glycol. 
Vodena farmaceutska-suspenzija u skladu s patentnim zahtjevom 7, naznačena time što izborno dodatno sadrži, težinski/volumno (g/100 ml), otprilike 2,5 % do otprilike 5,0 % propilen-glikola.
In case e.g. an O-ring is placed on the side wall 7 of the capsule 1, the radial component of the compression force will prevail. 
U slučaju da se, na primjer, O-prsten stavi na bočnu stijenku 7 čahure 1, prevladati će radijalna komponenta sile stlačivanja.
Pump 40 would pull mixture from bottle 20 at the desired rate. 
Pumpa 40 će izvlačiti mješavinu iz boce 20 željenom brzinom.
The set as claimed in claim 11, wherein the mechanical locking system at the third and the fourth edge is configured to be assembled by an angling motion. 
Komplet prema patentnom zahtjevu 7 ili 8, naznačen time što je mehanički sustav zaključavanja na trećem i četvrtom rubu izveden tako da se sklapa pomicanjem pod kutom.
A compound, or a pharmaceutically acceptable salt thereof, for use according to claim 5, wherein administration is via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što se primijenjuje kroz dozator za lijek koji se bira iz skupine koju čine inhalator sa spremnikom za suhi prah, višedozni inhalator sa suhim prahom i inhalator za odmjerene doze.
K2O and Na2O in a total amount of 1 to 6 weight %. 
O i Na2 O u ukupnoj količini od 1 do 6 tež.%.
The process of embodiment 3 wherein at least one of (i) viscosity of the suspension containing the fibrids, (ii) size of the fibrids, or (iii) shape of the fibrids is controlled by altering at least one process parameter wherein the process parameter is the dope concentration, the type of mixer, the mixing speed, the pH of precipitation bath, the rate of addition of solvent in which poly alpha-(1,3)-glucan is dissolved, the amount of non-solvent used, the duration of mixing, the rate of neutralization, and/or the concentration of neutralizer. A process for making fibrids comprising: 
Postupak u skladu s patentnim zahtjevom 3, pri čemu najmanje jedno od (i) viskoznosti suspenzije koja sadrži fibride, (ii) veličine fibrida ili (iii) oblika vlakana kontrolirano je mijenjanjem najmanje jednog parametra postupka, pri čemu je parametar postupka koncentracija aktivne tvari, vrsta miksera, brzina miješanja, pH vrijednost taložene otopine, stopa dodavanja otapala u kojem je otopljen poli alfa-(1,3)-glukan, količina korištenog ne-otapala, trajanje miješanja, stopa neutralizacije i/ili koncentracija neutralizatora.
In order to make sure that a relatively soft contact is made between the surface of the workpiece and the laminated disc 1, the thickness of the compressible lamellas 4 is preferably at least equal to three times the thickness of said sanding lamellas 3. 
Da bi se osiguralo da se učini relativno mekan kontakt između površine komada koji se treba obraditi i lameliranog diska 1, poželjno je da je debljina lamela koje se mogu komprimirati 4 najmanje jednaka trostrukoj debljini navedenih lamela za brušenje 3.
Technical tights according to claim 1, characterized in that the parts having terry knitting are localized depending on the supposed use for the same tights, and in particular in the zones more subject to wearing. 
Specijalne čarape prema zahtjevu 1, naznačene time što se dijelovi s frotirnim tkanjem nalaze na područjima ovisno o namjeni tih čarapa i posebno na dijelovima koji su izloženiji trošenju.
The antibody or antigen-binding portion thereof of claim 1 or 2, comprising a heavy chain variable region that is at least 95% identical to the amino acid sequence of SEQ ID NO:61; and/or a light chain variable region that is at least 95% identical to the amino acid sequence of SEQ ID NO:62. 
Protutijelo ili njegov dio koji veže antigen prema zahtjevu 1 ili 2, koje obuhvaća varijabilnu regiju teškog lanca koja je barem 95% identična sekvenci aminokiselina SEQ ID NO:61; i/ili varijabilnu regiju lakog lanca koja je barem 95% identična sekvenci aminokiselina SEQ ID NO:62.
It has also been shown that the metabolites of rapamycin can undergo this ester hydrolysis. 
Također je pokazano da metaboliti rapamicina mogu ući u hidrolizu estera.
The compounds of the present invention may also be resolved by the formation of diastereomeric derivatives. 
Racemički spojevi ovdje predočenog izuma mogu se pretvoriti u njihove optičke antipode i frakcionalnom kristalizacijom spojevi ovdje predočenog izuma mogu se pretvarati formacijom diastereomeričkih derivata.
Amino substituted sugar derivatives, e.g, sugar-X—NH2 or sugar-NH2, can be prepared from precursors by conventional methods. 
Amino-supstituirani šećerni derivati, npr. šećer-X-NH> ili šećer-NH, mogu se pripremiti iz prekursora uobičajenim postupcima.
Maintaining a closed system between the mixture in bottle 20 and nozzle 12 deters any drying action that could be detrimental to biologically active or chemical substances. 
Održavanje zatvorenog sustava između mješavine u boci 20 i mlaznice 12 isključuju bilo kakvo sušenje koje bi moglo biti razarajuće za biološki aktivne ili kemijske supstance. c.
In a third aspect, the present invention relates to a kit comprising compound 6, particularly a kit comprising at least 100 mg of compound 6,and at least one additional reagent for the synthesis of amatoxins or precursors thereof. 
Komplet koji sadržava spoj 6, naznačen time, da osobito sadržava najmanje 100 mg spoja 6 i jedan ili više dodatnih reagensa za sintezu amatoksina ili njihovih prekursora.
A compound of claim 1 for use in treating cancer, wherein said cancer is breast cancer, ovarian cancer, prostate cancer, non-small cell lung cancer, colon cancer, gastric cancer, pancreatic cancer or glioma. 
Spoj prema zahtjevu 28, naznačen time da navedeni rak je rak dojke, rak jajnika, rak prostate, rak pluća ne-malih stanica, rak debelog crijeva, rak želuca, rak gušterače ili gliom.
Samples were taken and the fraction discarded. 
Uzorci su bili sačuvani, a frakcija je bila odbačena.
optionally obtaining the metabolization product, the metabolization product preferably being selected from the group of bio-based chemicals or biofuels, such as lactic acid, acetic acid, succinic acid, malic acid, 1-butanol, isobutanol, 2-butanol, other alcohols, amino acids, 1,3-propanediol, ethylene, glycerol, a B-lactam antibiotic or a cephalosporin, alkanes, terpenes, isoprenoids or the precursor molecule amorphadiene of the antimalarial drug artemisinin, wherein the pentose is preferably arabinose, more preferably L-arabinose. 
izbornog dobivanja metaboličkog produkta, HR P20171423 T1 gdje se metabolički produkt po mogućnosti bira iz skupine biološki baziranih kemikalija ili biogoriva, poput mliječne kiseline, octene kiseline, jantarne kiseline, jabučne kiseline, 1-butanola, izobutanola, 2-butanola, drugih alkohola, aminokiselina, 1,3-propandiola, etilena, glicerola, B-laktamskog antibiotika ili cefalosporina, alkana, terpena, izoprenoida ili amorfadiena kao molekulskog preteče antimalaričnog lijeka artemizinina.
The agent for use according to claim 4, wherein the agent is for treating chronic renal failure. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što je sredstvo za liječenje kronične insuficijencije bubrega.
the heavy chain variable domain is SEQ ID NO:47 and the light chain variable domain is SEQ ID NO:48, or 
varijabilna domena jakog lanca je SEQ ID NO:47 i varijabilna domena slabog lanca je SEQ ID NO:48, ili
measurement in the pharmaceutical formulation obtained in step b) of Cch l, the concentration of free lanthanide Clan 1 being equal to 0; adjustment of Cch 1 and of Clan 1 by eliminating free macrocyclic chelate from and/or by adding free lanthanide to and/or by modifying the pH of the formulation obtained in step b) so as to obtain Cch 1 = Ct ch 1 and Clan 1 = 0, wherein Ct ch 1 is the target concentration of the free macrocyclic chelate in the final liquid pharmaceutical formulation and is selected in the range of between 0.002 % and 0.4 % mol/mol, wherein the amount of free macrocyclic chelate in the final liquid pharmaceutical formulation corresponds to the proportion of free macrocyclic chelate relative to the amount of complexed macrocyclic chelate DOTA-Gd in the final liquid pharmaceutical formulation in mol/mol, wherein the macrocyclic chelate is DOTA and the lanthanide is gadolinium. 
Cc) mjerenje u farmaceutskoj formulaciji dobivenoj u koraku b) koncentracije slobodnog lantanida Cig 1; A koncentracija slobodnog makrocikličkog kelata Ci, 1 jednaka je 0; d) podešavanje Ca, 11 Cin 1 pomoću dodavanja u formulaciju dobivenu u koraku b) potrebne količine slobodnog makrocikličkog kelata, prvo, da se okonča kompleksiranje slobodnog lantanida tako da se dobije Cian 1 = 0, te drugo, da se dobije Ca, 1 = Cia 1> Pri čemu Ci a, 1 je ciljana koncentracija slobodnog makrocikličkog kelata u konačnoj tekućoj farmaceutskoj formulaciji, te je odabrana u rasponu od između 0.002 % i 0.4 % mol/mol, pri čemu količina slobodnog makrocikličkog kelata u konačnoj tekućoj farmaceutskoj formulaciji odgovara udjelu slobodnog makrocikličkog kelata u odnosu na količinu kompleksiranog makrocikličkog kelata u konačnoj tekućoj farmaceutskoj formulaciji.
at least one seal configured to enclose either or both the proximal end and the distal end of the chamber; and cells within the chamber. 
Uređaj sukladno zahtjevu 1, pri čemu najmanje jedna komora sadrži otvor na jednom ili oba od navedenih proksimalnog kraja ili distalnog kraja komore, i pri čemu uređaj sadrži:
wherein, upon authentication of the user's biometric data, the biometric device is disabled, and the e-wallet account of the user is made accessible to the user terminal; and 
Sustav za igranje sukladno bilo kojem od prethodnih patentnih zahtjeva, pri čemu je račun korisnikovog e- novčanika (71) dostupan uređaju za igru tijekom ograničenog vremenskog perioda.
An anti-VAP-1 antibody or VAP-1 binding fragments thereof, comprising a heavy chain polypeptide, wherein the heavy chain polypeptide comprises, in the following order, the CDR sequences set forth as SEQ ID NOS: 1, 2, and 3 and a light chain polypeptide, wherein the light chain polypeptide comprises, in the following order, the CDR sequences set forth as SEQ ID NOS: 24, 25, and 26, characterized in that it is fully human. 
Anti-VAP-1 protutijelo ili njegov vezni dio VAP-1, karakteriziran na način da je potpuno ljudski 1 sadrži polipeptid teškog lanca opisan slijedom identifikacijskog broja SEQ ID NO: 47 ili inačica njegovog nepromjenjivog slijeda, i polipeptid lakog lanca opisan u SEQ ID NO: 48 ili inačica njegovog nepromjenjivog slijeda; pri čemu anti-VAP-1 protutijelo ili njegov vezni dio VAP-1 pokazuje poboljšani profil koncentracije u serumu tijekom vremena (AUC) i produljeno poluvrijeme eliminacije u odnosu na kimerično anti-VAP-1 protutijelo nazvano BTT-1002.
Process according to claim 9, characterised in that step c) is carried out at a temperature of approximately 650°C, performing the steam reforming reactions from the carbon remaining in the gas stream. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što se korak c) provodi na temperaturi od otprilike 650°C, gdje se provode reakcije reformiranja vodenom parom iz ugljika preostalog u struji plina.